<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="270">
  <stage>Registered</stage>
  <submitdate>13/09/2001</submitdate>
  <approvaldate>13/09/2001</approvaldate>
  <nctid>NCT00023894</nctid>
  <trial_identification>
    <studytitle>Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer</studytitle>
    <scientifictitle>A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GOG-0129M</secondaryid>
    <secondaryid>CDR0000068874</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - alvocidib

Treatment: drugs: alvocidib


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary endometrial carcinoma

               -  Recurrent or persistent disease

               -  Refractory to curative therapy or established treatment

          -  Previously treated with only 1 prior cytotoxic chemotherapy regimen (either single
             agent or combination therapy) for endometrial carcinoma

               -  Initial treatment may include high-dose, consolidation, or extended therapy
                  administered after surgical or non-surgical assessment

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR

               -  At least 10 mm by spiral CT scan

               -  At least 1 target lesion outside previously irradiated field

          -  Ineligible for higher priority Gynecologic Oncology Group (GOG) protocol, defined as
             any active GOG phase III protocol for the same patient population

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Performance status:

          -  GOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT no greater than 2.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  PT/PTT normal

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Cardiovascular:

          -  No prior thromboembolic events or thrombophlebitis

          -  No prior recent myocardial infarction

          -  No prior angina

          -  No prior cerebrovascular accident

          -  No prior transient ischemic attacks

        Other:

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No grade 2 or greater sensory or motor neuropathy

          -  No active infection requiring antibiotics

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 3 weeks since prior biologic or immunologic agents for endometrial carcinoma

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since prior chemotherapy for endometrial carcinoma and recovered

        Endocrine therapy:

          -  At least 1 week since prior hormonal therapy for endometrial carcinoma

          -  Concurrent hormone replacement therapy allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since prior radiotherapy for endometrial carcinoma and recovered

        Surgery:

          -  At least 3 weeks since prior surgery for endometrial carcinoma and recovered

          -  At least 6 months since prior re-vascularization procedures (e.g., coronary artery
             bypass graft, carotid endarterectomy or bypass, or angioplasty with or without stents)

        Other:

          -  At least 3 weeks since other prior therapy for endometrial carcinoma

          -  At least 6 months since prior thrombolytic procedures

          -  No prior cyclin-dependent kinase inhibitors

          -  No prior anticancer therapy that would preclude study

          -  No concurrent amifostine or other protective reagents</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Australia New Zealand Gynaecological Oncology Trials Group - Camperdown</hospital>
    <postcode>1450 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Gynecologic Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who
      have recurrent or persistent endometrial cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00023894</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edward C. Grendys, MD</name>
      <address>Robert H. Lurie Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>